

Table S1. Demographics and clinical features of RLS subjects.

Demographics, RLS characteristics, and treatment of PD subjects presenting RLS at the time of diagnosis (prevalent RLS) or developing RLS during the course of the disease (incident RLS) are reported (*: below normal values).

<i>RLS Subjects</i>		<i>Prevalent RLS</i>					<i>Incident RLS</i>															
Gender		M	M	M	F	M	M	F	M	M	M	F	M	M	F	M	F	F	M	M	F	F
Age at PD diagnosis, years		65	68	53	54	45	67	58	62	72	59	46	67	54	56	49	51	70	71	74	63	71
IRLSSG rating scale	<i>baseline</i>	16	14	9	15	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	<i>2-years</i>	-	15	-	-	-	-	18	9	-	-	-	8	9	-	11	-	-	8	-	-	-
	<i>4-years</i>	-	13	-	-	-	8	15	-	9	9	10	9	7	13	10	12	14	8	16	18	11
RLS family history		No	Yes	No	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No
Laboratory values	<i>Iron, ng/mL</i>	45	104	173	121	165	110	115	92	108	120	27	109	119	88	82	51	57	76	103	111	89
	<i>Ferritin, ng/mL</i>	25	274	217	198	215	174	190	155	90	125	57	106	108	112	98	78	81	91	130	155	222
	<i>Haemoglobin, g/dL</i>	13.1*	14.6	17.3	13.9	16.5	15.6	13.7	16.0	14.4	13.1*	10.6*	15.3	15.0	13.9	15.4	13.2	11.7*	14.2	16.1	15.9	14.4
	<i>Creatinine, mg/dL</i>	1.3	1.0	0.9	0.7	0.9	1.0	0.7	0.9	1.0	0.7	0.9	1.2	1.0	1.0	1.1	1.0	0.7	1.0	0.7	0.6	0.8
Motor subtype		TD	PIGD	PIGD	TD	ND	TD	ND	TD	TD	ND	TD	TD	ND	TD	TD	TD	TD	TD	PIGD	TD	ND
L-Dopa, mg/day	<i>2-years</i>	300	-	-	-	-	150	300	-	200	-	250	300	400	-	300	-	400	-	200	-	400
	<i>4-years</i>	450	300	300	-	-	250	400	200	400	300	400	500	400	-	500	100	400	200	300	100	500
DA agonist, type	<i>2-years</i>	PM	PM	-	PM	PM	-	PM	RP	-	PM	PM	-	PM	PM	PM	PM	-	PM	-	PM	-
	<i>4-years</i>	-	PM	-	PM	PM	-	-	RP	PM	PM	-	PM	PM	PM	-	PM	PM	-	-	PM	-
MAO-B, type	<i>2-years</i>	RA	-	SE	RA	-	RA	-	-	-	-	-	-	-	RA	-	RA	-	RA	RA	RA	-
	<i>4-years</i>	RA	RA	SE	RA	SE	RA	-	RA	-	-	RA	-	-	RA	SE	RA	RA	RA	RA	RA	-
LEDD	<i>2-years</i>	452	105	50	310	205	250	510	80	210	210	460	300	610	210	510	205	400	205	300	310	400
	<i>4-years</i>	550	505	350	415	305	350	610	380	452	405	500	605	610	310	810	305	605	405	400	410	500

Antidepressants	<i>2-years</i>	-	-	-	-	-	-	SER	-	-	-	-	-	-	-	SER	=	=	=	=	=
	<i>4-years</i>	ES	-	-	-	-	-	-	SER	-	-	-	-	-	ES	-	-	=	=	=	=
Clonazepam (mg)	<i>2-years</i>	-	-	-	-	-	-	10	-	-	-	-	-	-	-	-	=	=	=	=	=
	<i>4-years</i>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	=	=	=	=	=

RLS: restless legs syndrome; PD: Parkinson's disease; M: male; F: female; IRLSSG rating scale: International RLS Study Group rating scale; TD: tremor dominant phenotype; ND: not determined/mixed phenotype; PIGD: postural instability gait disorder phenotype; UPDRS: Unified Parkinson's Disease Rating Scale; DA: dopamine; IMAO-B: mono-amino-oxidase-B inhibitor; PM: pramipexole; RP: ropinirole; RA: rasagiline; SE: selegiline; LEDD: L-dopa equivalent daily dosage; SER: sertraline; ES: escitalopram.